Events Search and Views Navigation
August 2020
October 2020
FoCUS Design Lab
Invitation only.
Find out more »November 2020
LEAPS Design Lab #6
Invitation only.
Find out more »January 2021
California Life Sciences Association
Mark Trusheim spoke at a California Life Sciences Association briefing on January 26. The briefing was well attended, and the audience included California state legislators.
Find out more »February 2021
2021 Meetings of the ASTCT and CIBMTR
Mark Trusheim presented "Models of Paying for High-Cost Cellular Therapies" at the 2021 Meetings of the ASTCT and CIBMTR.
Find out more »BioNJ Cell & Gene Therapy Market Access Program
Mark Trusheim participated as a panelist in the BioNJ Cell & Gene Therapy Market Access Program for FoCUS.
Find out more »4th Annual Gene Therapy for Rare Disorders Conference
Mark Trusheim spoke at on the panel "Collecting & Utilizing Data to Support Gene Therapy Market Access" at the 4th Annual Gene Therapy for Rare Disorders conference representing FoCUS.
Find out more »MIT Sloan 2021 Healthcare and Bioinnovations Conference
NEWDIGS Executive Director Gigi Hirsch moderated the midday keynote fireside chat at the MIT Sloan 2021 Healthcare and Bioinnovations Conference, on the topic "The Value of Downstream Innovation - Improving Patient Access to Groundbreaking Therapies".
Find out more »March 2021
Gene Therapy for Blood Disorders Virtual Conference
Mark Trusheim spoke at on the panel "Collecting & Utilizing Data to Support Gene Therapy Market Access" at the 4th Annual Gene Therapy for Rare Disorders conference representing FoCUS.
Find out more »April 2021
ISPOR
On April 12 Mark Trusheim led a workshop for ISPOR, entitled “Adaptive Reimbursement: Innovating for Patient Access and Better Outcomes for All”, including Angela Banks Vice President, External Affairs, UnitedHealth Group; Ron Potts, MD; Medical Director Quality Improvement Kaiser Permanente, Chief Medical Officer, INTERLINK; and David Strutton, PhD, VP, Global Pharmaceuticals & Policy Research, Center for Observational and Real-World Evidence, Merck & Co. Mark recaps the panel in this AJMC update.
Find out more »